Zealand Pharma

Zealand Pharma evaluates all expanded access requests on an individual basis, depending on the asset, local regulatory requirements, and the availability of other treatments. 

For dasiglucagon in congenital hyperinsulinism (CHI): 
US patients diagnosed with CHI who have not responded adequately to other available treatments for CHI might be eligible for enrollment in an EAP treatment protocol. For requests, please contact dasiglucagon-eap@wepclinical.com. 

For requests for patients diagnosed with CHI in other countries, please contact dasiglucagon-eap@wepclinical.com

For other assets: 
Please contact: contact@medinfo.zealandpharma.com.